Baseline demographic characteristics*
| Placebo (n = 95) | Exisulind 200 mg (n = 91) | Exisulind 400 mg (n = 95) | |
|---|---|---|---|
| *There were no significant differences between treatment groups for sex, age, race, weight, or body mass index for all patients enrolled (n = 281), the intention to treat population (n = 155), or the efficacy evaluable population (n = 114). | |||
| Sex (n (%)) | |||
| Male | 68 (72%) | 59 (65%) | 60 (63%) |
| Female | 27 (28%) | 32 (35%) | 35 (37%) |
| Age (y) | |||
| Mean (SD) | 61.1 (10.7) | 60.2 (10.4) | 58.3 (11.2) |
| Range | 22–85 | 37–85 | 33–82 |
| Race (n (%)) | |||
| White | 85 (90%) | 82 (90%) | 88 (93%) |
| Black | 8 (8%) | 8 (9%) | 6 (6%) |
| Asian | 1 (1%) | 0 (0%) | 0 (0%) |
| Other | 1 (1%) | 1 (1%) | 1 (1%) |
| Weight (kg) | |||
| Mean (SD) | 85.1 (16.1) | 86.4 (15.7) | 84.6 (16.7) |
| Range | 49.5–139.5 | 55.8–124.0 | 52.5–126.8 |
| Mean (SD) body mass index | 28.5 (4.5) | 29.1 (4.8) | 28.8 (5.4) |